Showing 15 posts of 28 posts found.

Roche says combination therapy with its Avastin and Tarceva gets European backing for lung cancer treatment

June 8, 2016
Research and Development, Sales and Marketing European Commission, NSCL, RegulationC, Roche, Tarceva, avastin, drug trial, lung cancer

Cancer drugmaker Roche (SIX: ROG) on Wednesday said the European Commission has approved its Avastin (bevacizumab) in combination with Tarceva …


Giotrif increases lung cancer survival

May 16, 2014
Research and Development, Sales and Marketing Boehringer, Iressa, Roche, Tarceva, afatinib, giotrif, lung cancer

Boehringer Ingelheim is trumpeting overall survival results from a new analysis of two late-stage studies involving Giotrif in lung cancer …


NHS needs to understand drug costs better, says ABPI

April 10, 2014
Medical Communications, Research and Development, Sales and Marketing ABPI, AGNSS, Deepak Khanna, NICE, Stephen Whitehead, Tarceva, soliris

The UK healthcare system is at risk of failing to adopt new, personalised medicines and must be willing to pay …


NICE U-turn on Roche cancer drug

April 4, 2014
Medical Communications, Sales and Marketing NICE, Roche, Tarceva, U-turn

Roche’s lung cancer drug Tarceva has been given a reprieve to treat relapsed lung cancer patients in the NHS after …


Roche lung cancer drug fails

March 3, 2014
Research and Development, Sales and Marketing Cancer, MetMAb, NSCLC, Roche, Tarceva, avastin

An independent data monitoring committee has told Roche to halt a study of its experimental lung cancer drug MetMab due …

Roche image

Roche: NICE guidance ‘perverse’

February 4, 2014
Sales and Marketing NHS, NICE, NSCLC, Roche, Tarceva

Roche has poured scorn on NICE’s ‘perverse’ recommendation that its EGFR-TK inhibitor Tarceva should no longer be given to NHS …

Pfizer image

Pfizer lung cancer drug suffers late-stage setback

January 28, 2014
Research and Development, Sales and Marketing Cancer, NSCLC, Pfizer, Roche, Tarceva, dacomitinib

An experimental cancer drug developed by Pfizer has failed in two separate Phase III clinical studies. Dacomitinib is a tyrosine …


FDA approves Boehringer’s lung cancer drug

July 12, 2013
Medical Communications, Sales and Marketing Boehringer, FDA, Roche, Tarceva, afatinib, lung cancer

Boehringer Ingelheim’s late-stage lung cancer drug Gilotrif has received an accelerated FDA approval for patients with a certain genetic mutation. …

Boehringer submits new lung cancer drug

September 20, 2012
Research and Development, Sales and Marketing Boehringer, NSCLC, Roche, Tarceva, afatinib

Boehringer Ingelheim has filed its new lung cancer drug with the EMA. Afatinib is the latest targeted therapy for lung …

Tarceva image

NICE final yes for Zytiga and Tarceva

June 27, 2012
Sales and Marketing Janssen, NHS, NICE, NSCLC, Roche, Tarceva, Zytiga

In final guidance published today, NICE is recommending two new drugs for patients with prostate and lung cancer. Janssen’s Zytiga …

Tarceva image

Discount sways NICE into recommending Tarceva

May 10, 2012
Sales and Marketing Iressa, NICE, NSCLC, Roche, Tarceva, lung cancer

NICE is recommending Roche’s lung cancer pill Tarceva in patients with a certain type of the disease.  The watchdog said …

Tarceva image

NICE no for first line Tarceva

February 17, 2012
Sales and Marketing CDF, Cancer, NICE, Roche, Tarceva

NICE no for first line Tarceva Watchdog wants more information on Roche’s drug NICE is not recommending Roche’s lung cancer …

Roche’s Lung cancer test approved for Europe

December 5, 2011
Research and Development, Sales and Marketing Roche, Tarceva, lung cancer

A new test which should help to better target treatment of patients with non-small cell lung cancer (NSCLC) has received …

Roche's Tarceva (erlotinib)

Tarceva approval for first-line use in EGFR lung cancer

September 1, 2011
Sales and Marketing NSCLC, Roche, Tarceva

Tarceva has been granted final European approval for patients with a genetically distinct type of non-small cell lung cancer (NSCLC). …

Roche's Tarceva (erlotinib)

Roche cancer drug Tarceva set for first-line licence

July 25, 2011
Sales and Marketing Cancer, Roche, Tarceva

Roche’s cancer drug Tarceva is on course to win a first-line indication in Europe for the first time after regulatory …

Latest content